“We believe this Phase 2a study, with the limitations of a small sample size, supports that COYA 101 was well tolerated and biologically active in ALS patients and may slow or halt disease progression in the right patient population. We believe the findings that high levels of inflammation and oxidative stress may limit the effectiveness of Tregs, resulting in shorter cell half-lives and impacting their downstream suppressive anti-inflammatory effects, may help to better enhance the signal by prospectively identifying the patients with the higher likelihood to respond”, said Howard Berman, PhD, CEO, Coya Therapeutics Inc.
Leaving the Tumor Behind: ADCs in Non-Oncology Indications
In this week’s ADC Spotlight, Suhail Ahmed Kabeer Rasheed takes the ADC platform somewhere it has rarely been
